<h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>SinoMab Bioscience Ltd. ( (HK:3681) ) 的最新动态现已发布。</p>
<p>SinoMab BioScience Limited 宣布其针对炎症性肠病 (IBD) 的新药申请 SM17 已获得中国国家药品监督管理局的接受。这一进展标志着 SM17 的应用从特应性皮炎扩展到包括克罗恩病和溃疡性结肠炎等慢性疾病的重要一步。SM17 独特的作用机制涉及调节 II 型炎症反应，使其成为应对 IBD 复杂病理的有前景的候选药物，可能为难治性或复杂疾病表型的患者提供新的治疗选择。公司预计，这一扩展将通过满足重大的临床和商业需求，显著影响其市场地位。</p>
<p>对 (HK:3681) 股票的最新分析师评级为持有，目标价为 HK$1.50。要查看 SinoMab Bioscience Ltd. 股票的完整分析师预测列表，请访问 HK:3681 股票预测页面。</p>
<p><strong>关于 SinoMab Bioscience Ltd. 的更多信息</strong></p>
<p>SinoMab BioScience Limited 是一家专注于新型治疗性抗体开发的生物技术公司。该公司在制药行业运营，主要强调为炎症性疾病（包括特应性皮炎和炎症性肠病）开发治疗方案。SinoMab 旨在通过利用其在抗体开发方面的专业知识，解决这些领域中重大的未满足医疗需求。</p>
<p><strong>平均交易量：</strong> 7,264,409</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> HK$1.95B</p>
<p>要深入了解 3681 股票，请访问 TipRanks 的概述页面。</p>

<p>SinoMab BioScience Limited 针对 SM17 的新药临床试验申请已被中国国家药品监督管理局接受，该药物针对炎症性肠病。这标志着 SM17 的应用范围从特应性皮炎显著扩展到包括克罗恩病和溃疡性结肠炎等慢性疾病，可能为复杂的炎症性肠病病例提供一种新颖的治疗选择。公司预计这一发展将通过满足重大临床和商业需求来增强其市场地位</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>An update from SinoMab Bioscience Ltd. ( (HK:3681) ) is now available.</p>
<div class="lb-trans"><p>SinoMab Bioscience Ltd. ( (HK:3681) ) 的最新动态现已发布。</p>
</div><p>SinoMab BioScience Limited announced that its Investigational New Drug application for SM17, targeting Inflammatory Bowel Disease (IBD), has been accepted by China’s National Medical Products Administration. This development marks a significant step in expanding SM17’s application beyond atopic dermatitis to include chronic conditions like Crohn’s disease and ulcerative colitis. SM17’s unique mechanism of action, which involves modulating Type II inflammatory responses, positions it as a promising candidate for addressing the complex pathology of IBD, potentially offering a novel treatment option for patients with refractory or complex disease phenotypes. The company anticipates that this expansion could significantly impact its market position by addressing substantial clinical and commercial needs.</p>
<div class="lb-trans"><p>SinoMab BioScience Limited 宣布其针对炎症性肠病 (IBD) 的新药申请 SM17 已获得中国国家药品监督管理局的接受。这一进展标志着 SM17 的应用从特应性皮炎扩展到包括克罗恩病和溃疡性结肠炎等慢性疾病的重要一步。SM17 独特的作用机制涉及调节 II 型炎症反应，使其成为应对 IBD 复杂病理的有前景的候选药物，可能为难治性或复杂疾病表型的患者提供新的治疗选择。公司预计，这一扩展将通过满足重大的临床和商业需求，显著影响其市场地位。</p>
</div><p>The most recent analyst rating on (HK:3681) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.</p>
<div class="lb-trans"><p>对 (HK:3681) 股票的最新分析师评级为持有，目标价为 HK$1.50。要查看 SinoMab Bioscience Ltd. 股票的完整分析师预测列表，请访问 HK:3681 股票预测页面。</p>
</div><p><strong>More about SinoMab Bioscience Ltd.</strong></p>
<div class="lb-trans"><p><strong>关于 SinoMab Bioscience Ltd. 的更多信息</strong></p>
</div><p>SinoMab BioScience Limited is a biotechnology company focused on the development of novel therapeutic antibodies. The company operates in the pharmaceutical industry, with a primary emphasis on creating treatments for inflammatory diseases, including atopic dermatitis and inflammatory bowel disease. SinoMab aims to address significant unmet medical needs in these areas by leveraging its expertise in antibody development.</p>
<div class="lb-trans"><p>SinoMab BioScience Limited 是一家专注于新型治疗性抗体开发的生物技术公司。该公司在制药行业运营，主要强调为炎症性疾病（包括特应性皮炎和炎症性肠病）开发治疗方案。SinoMab 旨在通过利用其在抗体开发方面的专业知识，解决这些领域中重大的未满足医疗需求。</p>
</div><p><strong>Average Trading Volume:</strong> 7,264,409</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 7,264,409</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> HK$1.95B</p>
<div class="lb-trans"><p><strong>当前市值：</strong> HK$1.95B</p>
</div><p>For an in-depth examination of 3681 stock, go to TipRanks’ Overview page.</p>
<div class="lb-trans"><p>要深入了解 3681 股票，请访问 TipRanks 的概述页面。</p>
</div>

SinoMab 公司用于治疗 IBD 的 SM17 新药临床试验申请已获 NMPA 受理